Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Recruiting · NCT07313462 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Strasbourg, France
View the official record on ClinicalTrials.gov →What this trial is about
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
Who can take part
Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with RRMS onset after age 50
- Patients who started their first disease-modifying therapy within 2 years of the first symptoms
- Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
- Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)
Exclusion criteria
- \- Patients with early progressive MS
Where it is running
1 location listed.
- Centre d'Investigation Clinique - CHU de Strasbourg - France - Strasbourg, France